AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Theriva Biologics reports Q3 results, extends cash runway to Q1 2027.
ByAinvest
Thursday, Nov 13, 2025 8:51 am ET1min read
Theriva Biologics presented data on its VCN-01 treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) in the VIRAGE Phase 2b trial at ESMO 2025. The company also presented preclinical data on its VCN-12 oncolytic virus at ESGCT 2025. Theriva Biologics reported $7.5 million in cash and equivalents as of September 30, 2025, which increased to $15.5 million after recent capital raises, extending liquidity until Q1 2027.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet